Biofarm Bucure (BIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biofarm Bucure (BIO) has a cash flow conversion efficiency ratio of 0.054x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RON28.64 Million ≈ $6.58 Million USD) by net assets (RON534.78 Million ≈ $122.79 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIO net asset quality score to measure how much of total assets are equity-financed.
Biofarm Bucure - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Biofarm Bucure's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Biofarm Bucure's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Biofarm Bucure Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biofarm Bucure ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Shengda Pharm
SHG:603079
|
0.028x |
|
Repay Holdings Corp
NASDAQ:RPAY
|
0.035x |
|
Mehadrin
TA:MEDN
|
-0.080x |
|
ASOS PLC UN.ADR 1 LS-035
F:DYQ0
|
N/A |
|
Rossari Biotech Limited
NSE:ROSSARI
|
0.024x |
|
Global Indemnity PLC
NYSE:GBLI
|
0.010x |
|
Andfjord Salmon AS
OL:ANDF
|
-0.012x |
|
Silver Tiger Metals Inc
V:SLVR
|
-0.008x |
Annual Cash Flow Conversion Efficiency for Biofarm Bucure (2019–2024)
The table below shows the annual cash flow conversion efficiency of Biofarm Bucure from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see BIO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | RON478.26 Million ≈ $109.82 Million |
RON57.59 Million ≈ $13.22 Million |
0.120x | -34.47% |
| 2023-09-30 | RON434.41 Million ≈ $99.75 Million |
RON79.83 Million ≈ $18.33 Million |
0.184x | +140.68% |
| 2022-09-30 | RON380.06 Million ≈ $87.27 Million |
RON29.02 Million ≈ $6.66 Million |
0.076x | -63.27% |
| 2021-09-30 | RON332.79 Million ≈ $76.41 Million |
RON69.18 Million ≈ $15.89 Million |
0.208x | +53.41% |
| 2020-09-30 | RON291.55 Million ≈ $66.94 Million |
RON39.51 Million ≈ $9.07 Million |
0.136x | -52.22% |
| 2019-09-30 | RON257.23 Million ≈ $59.06 Million |
RON72.96 Million ≈ $16.75 Million |
0.284x | -- |
About Biofarm Bucure
Biofarm S.A. manufactures and sells medicines in Romania. The company offers a portfolio of products covering therapeutic areas, such as antiallergics, cardiovascular and circulatory, analgesics and antipyretics, dermatology, digestive and metabolic, endocrine, genitourinary, multivitamins, ophthalmology, musculoskeletal, respiratory and ENT, and neurology. It provides prescription and non-prescr… Read more